Actuate Therapeutics, Inc.
ACTU Nasdaq
SEC CIK 1652935
Follow Actuate Therapeutics
Weekly email: filings, results
Net income
−$3.4M
+36.7% vs same quarter last year
EPS, diluted
−$0.14
+44% vs same quarter last year
Operating cash flow
−$3M
+55.8% vs same quarter last year
Operating income
−$3.4M
+37.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$22.2M |
| FY24 | −$27.3M |
| FY23 | −$24.7M |
| FY22 | - |